Compare Stocks → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:ARANASDAQ:CLBSOTCMKTS:HEMA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAAmerican Renal Associates$11.52$11.50$5.57▼$11.98$397.94M1.11106,940 shs9,831 shsCLBSCaladrius Biosciences$6.37$0.38▼$1.24$26.05M0.91522,308 shs466,373 shsHEMAHemaCare$25.31+0.6%$25.31$8.62▼$26.23$346.52M1.4739,950 shs5,400 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAAmerican Renal Associates0.00%0.00%0.00%0.00%0.00%CLBSCaladrius Biosciences0.00%0.00%0.00%0.00%0.00%HEMAHemaCare0.00%0.00%0.00%0.00%0.00%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARAAmerican Renal AssociatesN/AN/AN/AN/AN/AN/AN/AN/ACLBSCaladrius BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AHEMAHemaCareN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARAAmerican Renal AssociatesN/AN/AN/AN/ACLBSCaladrius BiosciencesN/AN/AN/AN/AHEMAHemaCareN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARAAmerican Renal Associates$822.52M0.48$1.69 per share6.80$2.59 per share4.45CLBSCaladrius BiosciencesN/AN/AN/AN/A$1.54 per shareN/AHEMAHemaCareN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARAAmerican Renal Associates-$13.79M$0.26N/AN/AN/A-2.04%-3.56%-0.24%N/ACLBSCaladrius Biosciences-$27.47M-$0.41N/AN/AN/AN/A-27.24%-26.08%N/AHEMAHemaCareN/AN/A0.00∞N/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARAAmerican Renal AssociatesN/AN/AN/AN/AN/ACLBSCaladrius BiosciencesN/AN/AN/AN/AN/AHEMAHemaCareN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARAAmerican Renal Associates7.541.051.02CLBSCaladrius BiosciencesN/A22.3322.33HEMAHemaCareN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipARAAmerican Renal Associates78.42%CLBSCaladrius Biosciences15.57%HEMAHemaCareN/AInsider OwnershipCompanyInsider OwnershipARAAmerican Renal Associates9.50%CLBSCaladrius Biosciences2.20%HEMAHemaCare26.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableARAAmerican Renal Associates4,97734.54 millionN/AOptionableCLBSCaladrius Biosciences2760.58 million59.25 millionOptionableHEMAHemaCareN/A13.69 millionN/ANot OptionableARA, HEMA, and CLBS HeadlinesSourceHeadlineDonors flock to blood centers following Union Station shootingmsn.com - February 21 at 11:59 PMLeukapheresis Market size worth $ 100647.54 Million, Globally, by 2028 at 6.08% CAGR: Verified Market Research®prnewswire.co.uk - November 7 at 12:50 PMHEMA Historical Datainvesting.com - October 22 at 8:02 PMPlasmapheresis Periprocedural Care Equipments Market Is Likely to Grasp the CAGR of 5.20% By 2029pharmiweb.com - October 3 at 1:05 PMPrimary Cells Market worth $2.8 billion | MarketsandMarketsfinanznachrichten.de - July 6 at 12:35 PMThe worldwide Therapeutic Plasma Exchange industry is currently experiencing significant growth and expanding at a 13.6% CAGR from 2023 - 2030marketwatch.com - June 22 at 8:29 PMPowering Hope: Bone Marrow Transplantation Market Set to Grow at a Robust CAGR of 3.7% through 2023-2028| HemaCare, ReeLabs Pvt. Ltd.medgadget.com - June 7 at 2:40 PMPrimary Hepatocytes Market Set to Skyrocket with a Staggering CAGR of 6.6% by 2023-2032| Lonza, Corning Inc.medgadget.com - June 6 at 6:38 PMRegion-Wise Apheresis Machines Market Analysis Forecast 2023-2030marketwatch.com - May 16 at 8:20 AM2023 Apheresis Machines Market Price & News with Size Forecast 2030marketwatch.com - May 14 at 8:34 AMPeripheral Blood Market upto 2030marketwatch.com - May 14 at 1:11 AM2023 Bone Marrow Transplant Market: Trends and Forecast 2031 | A Detailed Sales Channel Analysis Reportmarketwatch.com - May 9 at 12:43 AMResearch Use Human Cells Market 2023 Size, Status and Global Outlook -Charles River, Lonza, Thermo Fisher Scientific, Sigma-Aldrichmarketwatch.com - May 4 at 3:19 AMApheresis Equipment Market Size 2023, Industry Share, Growth, Trends, Revenue Analysis 2023-2030marketwatch.com - May 3 at 5:17 PMBone Marrow Transplant Market Growth Opportunities and Emerging Trends till 2031marketwatch.com - May 3 at 12:17 PMApheresis Devices Market Complete Overview till 2031marketwatch.com - April 28 at 9:07 PMGlobal Continuous Flow Apheresis Device Market Growth, Size and Manufacturers Analysis Research Report and Forecast 2023-2030 By VMReportsmarketwatch.com - April 15 at 10:45 PMPeripheral Blood Market Forecasted from 2023-2030marketwatch.com - April 13 at 1:51 PMNavigating the Pharmaceutical Sterility Testing Market Growth Outlook by market Trends and market size Using a 6.9% CAGR from 2023 - 2030marketwatch.com - April 10 at 11:57 PMLeukapheresis Market | Extensive Growth by 2031marketwatch.com - April 6 at 8:06 AMBone Marrow Transplant Market 2023 Size and Forecast to 2031marketwatch.com - April 4 at 8:28 AMApheresis Machines Market Growth and Forecast till 2030marketwatch.com - March 28 at 8:56 AMTherapeutic Plasma Exchange Market Size By 2031marketwatch.com - March 24 at 1:32 AMApheresis Devices Market Growth and Forecast till 2028marketwatch.com - March 23 at 10:31 AMMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains ImminentLow VIX? 3 High Beta Stocks To Boost Your ReturnsMarch 27, 2024 9:01 AMView Low VIX? 3 High Beta Stocks To Boost Your ReturnsAll In: Is MicroStrategy Overleveraging Its Future on Bitcoin? March 26, 2024 6:05 AMView All In: Is MicroStrategy Overleveraging Its Future on Bitcoin? What is a Secular Bull Market? How to Identify this MarketApril 16, 2024 7:59 AMView What is a Secular Bull Market? How to Identify this MarketAll Headlines Company DescriptionsAmerican Renal AssociatesNYSE:ARAAmerican Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.Caladrius BiosciencesNASDAQ:CLBSCaladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.HemaCareOTCMKTS:HEMAHemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy. It offers human blood cellular components derived from peripheral blood, bone marrow, and cord blood; and a range of consulting services in standard operating procedure development, personnel training, and quality and regulatory compliance. The company's network of FDA-registered, GMP/GTP-compliant collection centers ensures donor materials available to customers, as well as for use within its isolation laboratory. The company has strategic partnership with Charles River Laboratories International Inc. for human immune system research. HemaCare Corporation was founded in 1978 and is headquartered in Northridge, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.